Skip to main content
Clinical Trials/NCT04573179
NCT04573179
Unknown
Not Applicable

Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of Clinical Significant Prostate Cancer in Lesions With Prostate Imaging Reporting and Data System Score 3

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 site in 1 country60 target enrollmentJuly 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostatic Neoplasms
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Enrollment
60
Locations
1
Primary Endpoint
detection rate
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study was to explore the effectiveness of 68Ga-PSMA PET/MRI for improving the detection of csPCa in lesions with PI-RADS score 3. This study is a prospective, observational study, single-center research. After recruiting patients who are suspected prostate cancer with a mpMRI PI-RADS version2 score of 3 and willing to perform prostate biopsy to identify the diagnosis, 68Ga-PSMA PET/MRI will be performed. Lesions will be reaccessed based on PET/MRI findings and compared with the pathological results.

Registry
clinicaltrials.gov
Start Date
July 1, 2020
End Date
July 1, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Responsible Party
Principal Investigator
Principal Investigator

Hongqian Guo

Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Eligibility Criteria

Inclusion Criteria

  • males over 18 years old suspected for prostate cancer
  • serum PSA between 4ng/ml and 20ng/ml in recent two months
  • mpMRI PI-RADS version2 scores 3 in recent two months
  • willing to undertake prostate biopsy
  • no evidence of non-cancerous factors interfere PSA level, such as catheter insertion, bladder stones, urinary tract infections or drug (e.g. finasteride)

Exclusion Criteria

  • history of prostate biopsy or other operations
  • history of prostate cancer associated treatment
  • contraindications for MRI or PET examination (e.g. claustrophobia, pacemakers, hip metal implants, hyperglycemia, glomerular filtration rate less than 50 ml/min)
  • not suitable for prostate biopsy (e.g. coagulation dysfunction, skin infection at perineal puncture site)

Outcomes

Primary Outcomes

detection rate

Time Frame: one year

detection rate of csPCa

Secondary Outcomes

  • detection rate(one year)

Study Sites (1)

Loading locations...

Similar Trials